NASDAQ:BRKR - Bruker Stock Price, News, & Analysis

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker declared a quarterly dividend on Friday, February 15th. Shareholders of record on Tuesday, March 5th will be given a dividend of $0.04 per share on Friday, March 22nd. This represents a $0.16 annualized dividend and a yield of 0.43%. The ex-dividend date is Monday, March 4th. View Bruker's Dividend History.

Bruker declared that its Board of Directors has initiated a share repurchase plan on Sunday, June 4th 2017, which authorizes the company to repurchase $225,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its stock is undervalued.

Bruker Co. (NASDAQ:BRKR) announced its quarterly earnings data on Monday, February, 11th. The medical research company reported $0.54 EPS for the quarter, meeting the consensus estimate of $0.54. The medical research company had revenue of $553.60 million for the quarter, compared to analysts' expectations of $544.53 million. Bruker had a return on equity of 27.23% and a net margin of 9.48%. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Bruker.

Bruker issued an update on its FY 2019 earnings guidance on Monday, February, 11th. The company provided EPS guidance of $1.54-1.58 for the period, compared to the Thomson Reuters consensus estimate of $1.55. The company issued revenue guidance of $2.009-2.028 billion, compared to the consensus revenue estimate of $1.97 billion.

5 analysts have issued 12 month price targets for Bruker's shares. Their predictions range from $30.00 to $44.00. On average, they anticipate Bruker's stock price to reach $35.80 in the next twelve months. This suggests that the stock has a possible downside of 4.1%. View Analyst Price Targets for Bruker.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 2 sell ratings, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bruker.

Media headlines about BRKR stock have been trending somewhat negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bruker earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.

Some companies that are related to Bruker include Waters (WAT), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM) and Arrayit (ARYC).

Bruker's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.49%), Acadian Asset Management LLC (2.55%), D. E. Shaw & Co. Inc. (1.36%), Bank of America Corp DE (0.86%), Epoch Investment Partners Inc. (0.86%) and Geode Capital Management LLC (0.83%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BTIM Corp., Prudential Financial Inc., QS Investors LLC, Citigroup Inc., D. E. Shaw & Co. Inc., Bank of Montreal Can and Assenagon Asset Management S.A.. View Insider Buying and Selling for Bruker.

BRKR stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Thrivent Financial for Lutherans, Bank of America Corp DE, Mackay Shields LLC, Segantii Capital Management Ltd, Millennium Management LLC, Canada Pension Plan Investment Board and Jane Street Group LLC. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $37.34.

Bruker has a market capitalization of $5.85 billion and generates $1.90 billion in revenue each year. The medical research company earns $179.70 million in net income (profit) each year or $1.40 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

The official website for Bruker is http://www.bruker.com.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]